Knowshine Pharmatech

Knowshine Pharmatech is a clinical-stage biopharmaceutical company specialized in the discovery and development of innovative small molecule drugs, with a particular focus on Targeted Protein Degradation (TPD). The company utilizes its proprietary platform to design and optimize PROTACs and molecular glues aimed at previously "undruggable" targets in oncology and immunology. Its lead programs include degraders targeting SHP2 and STAT3, which are currently being evaluated for their potential to treat various solid tumors and hematological malignancies. Based in Shanghai, Knowshine leverages a deep expertise in medicinal chemistry to bridge the gap between early-stage research and clinical therapeutic application.